Article
Antihypertensive therapy, the alpha-adducin polymorphism, and cardiovascular disease in high-risk hypertensive persons: the Genetics of Hypertension-Associated Treatment Study.
The pharmacogenomics journal - 1 Apr 2007
Davis B R, Arnett D K, Boerwinkle E, Ford C E, Leiendecker-Foster C, Miller M B, Black H, Eckfeldt J H
Abstract excerpt
In a double-blind, outcome trial conducted in hypertensive patients randomized to chlorthalidone (C), amlodipine (A), lisinopril (L), or doxazosin (D), the alpha-adducin Gly460Trp polymorphism was typed (n=36 913). Mean follow-up was 4.9 years. Relative risks (RRs) of chlorthalidone versus other treatments were compared between genotypes (Gly/Gly+Gly/Trp versus Trp/Trp). Primary outcome was coronary heart disease...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.